Results 171 to 180 of about 719,648 (264)
Exploring the Effects of Novel Food Processing Methods on Food Proteins: A Review. [PDF]
Wei S +7 more
europepmc +1 more source
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato +27 more
wiley +1 more source
The Development and Characterization of Biobased Film Formulations Made of Chitosan, Gelatine, and Gum Arabic with the Addition of Lemon Balm (<i>Melissa officinalis</i> L.) Extract as a Novel Food Packaging. [PDF]
Kurek M +5 more
europepmc +1 more source
Objective Gastrointestinal (GI) involvement can lead to malnutrition in patients with systemic sclerosis (SSc). Body mass index (BMI) remains the most widely used marker to screen nutritional status. We aimed to identify predictors of lower BMI in patients with SSc. Methods Patients with SSc from a prospective US cohort meeting 2013 American College of
Ali Y. Ayla +8 more
wiley +1 more source
Plant protein-phenolic acids as novel food-grade synergistic modulators of neuronal function: A review. [PDF]
Zhang X +5 more
europepmc +1 more source
Objective To evaluate utility of an artificial intelligence (AI) health coach for systemic sclerosis (SSc) self‐management and identify patterns associated with participant engagement. Methods We conducted a mixed methods study in which an AI health coach, powered by a large language model (LLM), was used to support self‐management for SSc.
Nirali Shah +4 more
wiley +1 more source
The novel food evaluation process delays access to food innovation in the European Union. [PDF]
Le Bloch J +5 more
europepmc +1 more source
From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis
Spondyloarthritis (SpA) is a group of chronic inflammatory diseases encompassing axial and peripheral forms, with up to 20% of patients developing symptoms before age 16. Despite this substantial pediatric burden, treatment options for juvenile‐onset SpA (JSpA), particularly those with axial disease (axJSpA), remain limited.
Pamela F. Weiss +9 more
wiley +1 more source

